The introduction of TNF-a blocking agents is one of the milestones in the therapy of rheumatoid arthritis, parallel to the introduction of cortico-steroids. Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, the book charts the history and development of the concept of tumor-necrosis-factor-alpha (TNF-a) inhibition. The authors document TNF-a from its discovery to its now well-documented clinical applications in the treatment of patients with rheumatoid arthritis. They compare and contrast practical management issues concerning the use of these agents both in the US and UK/Europe. The book is a practical and accessible source for the most recent information in this field.